Edwards Lifesciences Corp. (NYSE:EW) CEO Michael A. Mussallem sold 49,100 shares of Edwards Lifesciences Corp. stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $84.67, for a total value of $4,157,297.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Michael A. Mussallem also recently made the following trade(s):

  • On Thursday, October 27th, Michael A. Mussallem sold 49,100 shares of Edwards Lifesciences Corp. stock. The stock was sold at an average price of $92.77, for a total value of $4,555,007.00.

Edwards Lifesciences Corp. (NYSE:EW) traded up 2.14% during midday trading on Wednesday, reaching $86.86. The company had a trading volume of 2,208,193 shares. The stock’s 50 day moving average is $102.00 and its 200 day moving average is $106.84. Edwards Lifesciences Corp. has a one year low of $72.20 and a one year high of $121.75. The company has a market capitalization of $18.57 billion, a PE ratio of 34.33 and a beta of 0.71.

Edwards Lifesciences Corp. (NYSE:EW) last issued its quarterly earnings data on Tuesday, October 25th. The medical research company reported $0.68 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.68. The firm earned $739.40 million during the quarter, compared to the consensus estimate of $749.14 million. Edwards Lifesciences Corp. had a net margin of 19.24% and a return on equity of 24.32%. The business’s revenue for the quarter was up 20.1% compared to the same quarter last year. During the same period last year, the business posted $0.54 earnings per share. Equities research analysts forecast that Edwards Lifesciences Corp. will post $2.88 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Edwards Lifesciences Corp. (NYSE:EW)

A number of large investors have recently modified their holdings of the company. Columbus Circle Investors increased its stake in shares of Edwards Lifesciences Corp. by 1.6% in the second quarter. Columbus Circle Investors now owns 2,209,825 shares of the medical research company’s stock valued at $220,386,000 after buying an additional 33,790 shares during the period. Oregon Public Employees Retirement Fund increased its stake in Edwards Lifesciences Corp. by 74.7% in the third quarter. Oregon Public Employees Retirement Fund now owns 97,852 shares of the medical research company’s stock worth $11,797,000 after buying an additional 41,853 shares during the last quarter. Capital Fund Management S.A. increased its stake in Edwards Lifesciences Corp. by 10,543.8% in the second quarter. Capital Fund Management S.A. now owns 473,012 shares of the medical research company’s stock worth $47,173,000 after buying an additional 468,568 shares during the last quarter. Frontier Capital Management Co. LLC increased its stake in Edwards Lifesciences Corp. by 102.0% in the second quarter. Frontier Capital Management Co. LLC now owns 610,357 shares of the medical research company’s stock worth $60,871,000 after buying an additional 308,223 shares during the last quarter. Finally, Dorsey Wright & Associates increased its stake in Edwards Lifesciences Corp. by 5.9% in the third quarter. Dorsey Wright & Associates now owns 42,400 shares of the medical research company’s stock worth $5,112,000 after buying an additional 2,369 shares during the last quarter. Hedge funds and other institutional investors own 83.99% of the company’s stock.

A number of research analysts have recently weighed in on the company. Deutsche Bank AG lifted their price target on Edwards Lifesciences Corp. from $100.00 to $115.00 and gave the company a “hold” rating in a report on Wednesday, July 27th. JMP Securities lifted their price target on Edwards Lifesciences Corp. from $125.00 to $130.00 and gave the company a “market outperform” rating in a report on Thursday, July 28th. Wells Fargo & Co. reiterated a “buy” rating on shares of Edwards Lifesciences Corp. in a report on Sunday, September 11th. Citigroup Inc. lifted their price target on Edwards Lifesciences Corp. from $86.00 to $94.00 and gave the company a “sell” rating in a report on Wednesday, July 27th. Finally, Credit Suisse Group AG set a $116.00 price target on Edwards Lifesciences Corp. and gave the company a “buy” rating in a report on Thursday, August 18th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-two have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $117.68.

TRADEMARK VIOLATION WARNING: This story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2016/11/23/michael-a-mussallem-sells-49100-shares-of-edwards-lifesciences-corp-ew-stock.html.

About Edwards Lifesciences Corp.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

5 Day Chart for NYSE:EW

Receive News & Stock Ratings for Edwards Lifesciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp. and related stocks with our FREE daily email newsletter.